Cover Image
市場調查報告書

美國的乳癌治療藥市場未來展望

US Breast Cancer Drug Market Outlook 2022

出版商 KuicK Research 商品編碼 370683
出版日期 內容資訊 英文 130 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的乳癌治療藥市場未來展望 US Breast Cancer Drug Market Outlook 2022
出版日期: 2016年09月16日 內容資訊: 英文 130 Pages
簡介

本報告提供美國的乳癌的發病情形主要的治療藥的市場趨勢的分析,到目前為止的患病人數 (患者數) 、發病數量趨勢和今後預測,目前乳癌發病趨勢 (各人種的差異等),主要的風險要素,主要的治療藥簡介 (共18種:功效、副作用,銷售趨勢等) 等的相關調查。

第1章 美國的癌症盛行率

  • 概要
  • 過去的癌症發病數量:概要
  • 目前癌症發病頻率的趨勢
  • 今後的癌症發病數量的預測

第2章 美國的乳癌趨勢

  • 指標
  • 過去的乳癌發病數量:概要
  • 目前乳癌發病頻率的趨勢
  • 各年齡、各人種的乳癌發病頻率

第3章 乳癌風險的暗流有的東西

  • 荷爾蒙的影響
  • 家族病史、遺傳的原因
  • 老齡化與風險上升
  • 乳癌的管理

第4章 美國的乳癌藥市場概要

  • 各地區的銷售額
  • HER-2陽性乳癌用藥物的市場

第5章 美國的乳癌藥市場動態

  • 市場加速化要素、指標
  • 市場課題

第6章 美國的乳癌藥市場未來展望

美國的已上市的乳癌藥治療藥:企業方面、患者方面的觀點的臨床考察

第7章 Eribulin (Halaven)

  • 概要
  • 品牌名
  • 臨床實驗時的副作用相關記錄、報告

第8章 Trastuzumab Emtansine (Kadcyla)

第9章 Palbociclib (Ibrance)

第10章 Pertuzumab (Omnitarg & Perjeta)

第11章Gadobutrol (Gadavist, Gadovist & Gadovist 1.0)

第12章 Lapatinib (Tykerb)

第13章 Tamoxifen Oral Liquid (Soltamox)

第14章 Fulvestrant (Faslodex)

第15章 Anastrozole (Arimidex)

第16章 ikisabepiron (Ixempra)

第17章 toremifen (Fareston)

第18章 retorozoru (Femara)

第19章 Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene))

第20章 Exemestane (Aromasin)

第21章 維他命B12螢光類似體 (CobalaFluor Green & CobalaFluor Red)

第22章 Trastuzumab的搭配診斷藥 (HER2 CISH pharmDx)

第23章 Fluoxymesterone

第24章 競爭環境

  • Agilent Technologies
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals
  • Bristol-Myers Squibb
  • Eisai
  • Eli Lilly
  • Novartis
  • Onyx Pharmaceuticals
  • Orion
  • Perrigo
  • Pfizer
  • Roche
目錄

Around the corners of world, cancer has infused itself in every country, region and each habitable land present over earth. Cancer has become one of those nightmares which haunt every individual once in a life time this is because of the increasing incidence rates and no proper care available until now. Given the steady increase in global cancer incidence with its associated morbidity and mortality, together with the spiraling healthcare costs of treatment, there is increasing interest in this stringent disease.

Breast cancer is the second leading cause of mortality among women, after the Lung cancer. In United States it is the most common diagnosed form of cancer accounting for the ration of one is to three. As most type of cancers originates from a starting lump, so is the breast cancer. It is the breast tissue where the tumor generates in lobules and ducts that can be classified into invasive and non-invasive stages. A woman living in the US has a 12.3%, or a 1 in 8, lifetime risk of being diagnosed with breast cancer. In 2016, invasive breast cancer will be diagnosed in about 246,660 women and 2,600 men. An additional 61,000 new cases of in situ breast cancer will be diagnosed in women.

US breast cancer market is conquered by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). It was approved in 2012 by the FDA for the treatment of or late stage metastatic HER2-positive breast cancer patients.

Moreover, compounds such as Protein bound paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel and many more generic as well as branded drugs have shown positive results in reducing cancer progression and increasing life expectancy. Recently, branded drug such as Bevacizumab has seen preference among oncologists even though the drug has been advised to be removed from breast cancer indication. The market for metastatic breast cancer for now is highly fragmented between numerous drugs, radiation therapy and alternative therapies such as vitamin therapy, acupuncture, macrobiotic diets, homeopathy and herbal medication. Nano therapy via nano probe technology and various other areas of alternate treatment are under trials to check for their effectiveness in decreasing disease progression and arresting the cancerous cell growth by target specific tumor cell suppression.

Due to extensive research and development in treatment approaches for breast cancer. Breast cancer patients in US have a new surgical option that eliminates exposure to radioactive materials and offers a less invasive, alternative for cancer detection. This strategy has been approved by FDA and will be used to locate early stage tumors. The Sentimag technology platform is a magnetic surgical guidance probe used with nanoparticle tracers and other magnetic devices to more safely and easily determine the spread of cancer.

Historically, Herceptin has ruled the market in US and across the globe but due to its US patent expiration in 2019 its biosimilars might gain the same success stories. The driving forces behind the popularity of this drug are the increasing awareness of breast cancer by the means of several programs and screening aids. Another aspect is the emergence of targeted and combinational therapies. Drugs for the HER 2+ receptors such as Herceptin and Kadcyla can be administered as monotherapy or in the combination for the better survival rates. There are three specific medications that will be pushing this growth forward in breast cancer drug sales. These include; Novartis' Afinitor, Roche/Genentech's Perjeta, and trastuzumab-DM1. Afinitor has gained regulatory approval in Europe and the United States to market medication that treats hormone-receptor positive breast cancer, which is expected to raise this company's peak-year sales past US$ 1 Billion.

Ongoing clinical development of the drug Perjeta is also predicted to help it bring impressive sales through 2021. Targeted therapies are predicted to keep advancing the treatment of breast cancer. Breast cancer drug development is a hive of activity but despite the busy pipeline, forecast has been for the uptake of just three novel agents in this market through 2021. Moreover, two of these agents will penetrate only the HER2-positive market segment, which will continue to be dominated by Roche.

Indeed, Breast cancer is a difficult diagnosis to receive for any women, as these fears up for the low survival rates and every one in eight women develop the breast cancer throughout a lifetime. The healthcare sector and cancer drug market has focused on developing better treatments over the past years and new regimens are on the road to success.

"US Breast Cancer Drug Market Outlook 2022" Report Highlights:

  • US Breast Cancer Tendencies
  • US Breast Cancer Drug Market Outline
  • US Breast Cancer Drug Market Dynamics
  • Breast Cancer Risk Undercurrents
  • US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis
  • US Breast Cancer Marketed Drugs Clinical Insight: 18 Drugs

Table of Contents

1. US Cancer Prevalence Rate

  • 1.1 Overview
  • 1.2 Glimpse of Past Cancer Incidences
  • 1.3 Current Drifts in Cancer Frequencies
  • 1.4 Estimated Future Cancer Occurrences

2. US Breast Cancer Tendencies

  • 2.1 Indication
  • 2.2 Breast Cancer Historical Incidences
  • 2.3 Recent inclinations in Breast Cancer
  • 2.4 Breast Cancer Frequencies over Age & Race

3. Breast Cancer Risk Undercurrents

  • 3.1 Hormonal Aspects
  • 3.2 Family History & Genetic Predisposition
  • 3.3 Cumulative Age & Elevated Risk
  • 3.4 Management of Breast Cancer

4. US Breast Cancer Drug Market Outline

  • 4.1 Topographical Arcade Sales
  • 4.2 HER-2 Positive Drug Market

5. US Breast Cancer Drug Market Dynamics

  • 5.1 Breast Cancer Market Accelerative Parameters
  • 5.2 Breast Cancer Market Challenges

6. US Breast Cancer Drug Market Future Aspects

US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis

7. Eribulin (Halaven)

  • 7.1 Clinical Introduction
  • 7.2 Brand Names
  • 7.3 Recording & Reporting Of Clinical Adverse Events

8. Trastuzumab Emtansine (Kadcyla)

  • 8.1 Clinical Introduction
  • 8.2 Brand Names
  • 8.3 Recording & Reporting Of Clinical Adverse Events

9. Palbociclib (Ibrance)

  • 9.1 Clinical Introduction
  • 9.2 Brand Names
  • 9.3 Recording & Reporting Of Clinical Adverse Events

10. Pertuzumab (Omnitarg & Perjeta)

  • 10.1 Clinical Introduction
  • 10.2 Brand Names
  • 10.3 Recording & Reporting Of Clinical Adverse Events

11. Gadobutrol (Gadavist, Gadovist & Gadovist 1.0)

  • 11.1 Clinical Introduction
  • 11.2 Brand Names
  • 11.3 Recording & Reporting Of Clinical Adverse Events

12. Lapatinib (Tykerb)

  • 12.1 Clinical Introduction
  • 12.2 Brand Names
  • 12.3 Recording & Reporting Of Clinical Adverse Events

13. Tamoxifen Oral Liquid (Soltamox)

  • 13.1 Clinical Introduction
  • 13.2 Brand Names
  • 13.3 Recording & Reporting Of Clinical Adverse Events

14. Fulvestrant (Faslodex)

14.1 Clinical Introduction

  • 14.2 Brand Names
  • 14.3 Recording & Reporting Of Clinical Adverse Events

15. Anastrozole (Arimidex)

  • 15.1 Clinical Introduction
  • 15.2 Brand Names
  • 15.3 Recording & Reporting Of Clinical Adverse Events

16. Ixabepilone (Ixempra)

  • 16.1 Clinical Introduction
  • 16.2 Brand Names
  • 16.3 Recording & Reporting Of Clinical Adverse Events

17. Toremifene (Fareston)

  • 17.1 Clinical Introduction
  • 17.2 Brand Names
  • 17.3 Recording & Reporting Of Clinical Adverse Events

18. Letrozole (Femara)

  • 18.1 Clinical Introduction
  • 18.2 Brand Names
  • 18.3 Recording & Reporting Of Clinical Adverse Events

19. Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene))

  • 19.1 Clinical Introduction
  • 19.2 Brand Names

20. Exemestane (Aromasin)

  • 20.1 Clinical Introduction
  • 20.2 Brand Names
  • 20.3 Recording & Reporting Of Clinical Adverse Events

21. Vitamin B12 Fluorescent-Analogues (CobalaFluor Green & CobalaFluor Red)

  • 21.1 Clinical Introduction
  • 21.2 Brand Names

22. Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)

  • 22.1 Clinical Introduction
  • 22.2 Brand Names

23. Fluoxymesterone

  • 23.1 Clinical Introduction
  • 23.2 Recording & Reporting Of Clinical Adverse Events

24. Competitive Landscape

  • 24.1 Agilent Technologies
  • 24.2 AstraZeneca
  • 24.3 Bayer HealthCare Pharmaceuticals
  • 24.4 Bristol-Myers Squibb
  • 24.5 Eisai Co Ltd
  • 24.6 Eli Lilly
  • 24.7 Novartis
  • 24.8 Onyx Pharmaceuticals
  • 24.9 Orion
  • 24.10 Perrigo
  • 24.11 Pfizer
  • 24.12 Roche
Back to Top